Published in Br J Cancer on May 17, 2004
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol (2006) 3.12
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening. J Med Genet (2006) 2.68
An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res (2007) 2.46
Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. Proc Natl Acad Sci U S A (2006) 1.99
Breast cancer susceptibility: current knowledge and implications for genetic counselling. Eur J Hum Genet (2008) 1.82
BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer (2006) 1.65
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia (2005) 1.42
Associations between single nucleotide polymorphisms in double-stranded DNA repair pathway genes and familial breast cancer. Clin Cancer Res (2009) 1.02
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res (2009) 1.01
RAD51 and breast cancer susceptibility: no evidence for rare variant association in the Breast Cancer Family Registry study. PLoS One (2012) 0.93
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers. Br J Cancer (2008) 0.87
Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur J Cancer (2008) 0.87
Association between single nucleotide polymorphisms (SNPs) of XRCC2 and XRCC3 homologous recombination repair genes and triple-negative breast cancer in Polish women. Clin Exp Med (2014) 0.84
Association between the RAD51 135 G>C polymorphism and risk of cancer: a meta-analysis of 19,068 cases and 22,630 controls. PLoS One (2013) 0.84
Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. BMC Cancer (2011) 0.83
Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. BMC Cancer (2008) 0.81
Absence of founder BRCA1 and BRCA2 mutations in cutaneous malignant melanoma patients of Ashkenazi origin. Fam Cancer (2008) 0.79
Mutation analysis of the MDM4 gene in German breast cancer patients. BMC Cancer (2008) 0.79
Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Fam Cancer (2008) 0.78
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study. Genet Epidemiol (2013) 0.78
Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population. DNA Cell Biol (2011) 0.78
Tumor-associated mutations in a conserved structural motif alter physical and biochemical properties of human RAD51 recombinase. Nucleic Acids Res (2014) 0.78
Effects of the single nucleotide polymorphism at MDM2 309 on breast cancer patients with/without BRCA1/2 mutations. BMC Cancer (2009) 0.77
Polymorphisms of homologous recombination RAD51, RAD51B, XRCC2, and XRCC3 genes and the risk of prostate cancer. Anal Cell Pathol (Amst) (2015) 0.76
Polymorphisms in RAD51 and their relation with breast cancer in Saudi females. Onco Targets Ther (2016) 0.75
RAD51 135G>C substitution increases breast cancer risk in an ethnic-specific manner: a meta-analysis on 21,236 cases and 19,407 controls. Sci Rep (2015) 0.75
Differential expression of DNA repair genes in Hispanic women with breast cancer. Mol Cancer Biol (2013) 0.75
Association between RAD51 polymorphism and breast cancer susceptibility: a meta analysis. Int J Clin Exp Med (2015) 0.75
New single nucleotide polymorphisms (SNPs) in homologous recombination repair genes detected by microarray analysis in Polish breast cancer patients. Clin Exp Med (2016) 0.75
The RAD51 135G>C polymorphism is related to the effect of adjuvant therapy in early breast cancer. J Cancer Res Clin Oncol (2014) 0.75
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell (2002) 9.61
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell (2001) 5.59
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer. Am J Hum Genet (2002) 3.00
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am J Hum Genet (1999) 2.14
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A (2001) 2.09
Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet (2002) 2.04
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. Cancer Epidemiol Biomarkers Prev (2003) 0.99
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet (1995) 5.83
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Pendred syndrome is caused by mutations in a putative sulphate transporter gene (PDS). Nat Genet (1997) 4.43
Adenosine diphosphate as an intracellular regulator of insulin secretion. Science (1996) 4.42
Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med (1999) 4.22
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nat Genet (2000) 2.87
Beta-cell proliferation and apoptosis in the developing normal human pancreas and in hyperinsulinism of infancy. Diabetes (2000) 2.75
Familial hyperinsulinism with apparent autosomal dominant inheritance: clinical and genetic differences from the autosomal recessive variant. J Pediatr (1998) 2.33
The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet (1997) 2.28
The extent of linkage disequilibrium in four populations with distinct demographic histories. Am J Hum Genet (2000) 2.03
Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care (1997) 1.99
Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol (2000) 1.98
Sporadic imprinting defects in Prader-Willi syndrome and Angelman syndrome: implications for imprint-switch models, genetic counseling, and prenatal diagnosis. Am J Hum Genet (1998) 1.87
A nonsense mutation in the inward rectifier potassium channel gene, Kir6.2, is associated with familial hyperinsulinism. Diabetes (1997) 1.86
Mutations in the sulonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet (1996) 1.76
BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet (1995) 1.75
Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol (2001) 1.69
Basement membrane collagen: degradation by migrating endothelial cells. Science (1983) 1.67
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62
Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med (2012) 1.60
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol (1996) 1.59
Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes (1998) 1.59
Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes (1998) 1.53
Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol (2000) 1.52
Germline PTEN mutations in Cowden syndrome-like families. J Med Genet (1998) 1.51
A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: A novel founder mutation in Ashkenazi Jews. Hum Mutat (2001) 1.50
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. Magn Reson Imaging (2000) 1.47
Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women. Cytopathology (2001) 1.46
Germline BRCA1 mutations increase prostate cancer risk. Br J Cancer (2012) 1.45
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer (1998) 1.43
p57(KIP2) expression in normal islet cells and in hyperinsulinism of infancy. Diabetes (2001) 1.42
["Standards, Options and Recommendations 2001" for radiotherapy in patients with non-metastatic infiltrating breast cancer. Update. National Federation of Cancer Campaign Centers (FNCLCC)]. Cancer Radiother (2002) 1.39
Genetic testing for cancer predisposition--an ongoing debate. Lancet Oncol (2000) 1.39
Sampling distribution of summary linkage disequilibrium measures. Ann Hum Genet (2002) 1.36
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis (1995) 1.34
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? J Med Genet (1994) 1.33
The mechanisms involved in formation of deletions and duplications of 15q11-q13. J Med Genet (1998) 1.33
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Hum Genet (2011) 1.32
The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics (2001) 1.32
A genome scan for type 2 diabetes susceptibility loci in a genetically isolated population. Diabetes (2001) 1.31
Hand pattern indicates prostate cancer risk. Br J Cancer (2010) 1.29
Neurobehavioral phenotype in carriers of the fragile X premutation. Am J Med Genet (2001) 1.28
Environmental and dietary risk factors for nasopharyngeal carcinoma: a case-control study in Zangwu County, Guangxi, China. Br J Cancer (1994) 1.27
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br J Cancer (2001) 1.27
Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: high incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab (1995) 1.27
A multicopy dinucleotide marker that maps close to the spinal muscular atrophy gene. Genomics (1994) 1.22
Missense polymorphism in the human carboxypeptidase E gene alters enzymatic activity. Hum Mutat (2001) 1.21
No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis (1999) 1.21
Screening hCHK2 for mutations. Science (2000) 1.20
The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet (1999) 1.19
Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol (2009) 1.19
Analysis of four diverse population groups indicates that a subset of cystic fibrosis mutations occur in common among Caucasians. Am J Hum Genet (1992) 1.17
Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet (1997) 1.16
Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril (1996) 1.16
Cortisol and behavior in fragile X syndrome. Psychoneuroendocrinology (2002) 1.14
Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann syndrome due to defects in the function of pancreatic beta-cell adenosine triphosphate-sensitive potassium channels. J Clin Endocrinol Metab (2005) 1.14
Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis (2000) 1.12
Genetic heterogeneity in familial hyperinsulinism. Hum Mol Genet (1998) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Multimarker RT-PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients. Br J Cancer (2006) 1.12
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. Br J Cancer (2010) 1.11
Volatile nitrosamine levels in common foods from Tunisia, south China and Greenland, high-risk areas for nasopharyngeal carcinoma (NPC). Int J Cancer (1987) 1.11
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. Br J Cancer (1997) 1.10
Genetic predisposition to cancer: the consequences of a delayed diagnosis of Gorlin syndrome. Clin Oncol (R Coll Radiol) (2005) 1.08
Apoptosis, ageing and cancer susceptibility. Br J Cancer (2003) 1.08
Hyperinsulinism: molecular aetiology of focal disease. Arch Dis Child (1998) 1.08
Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood (1996) 1.08
Cost-benefit analysis of a national screening programme for cystic fibrosis in an Israeli population. Health Econ (1994) 1.08
Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique. J Clin Pathol (2005) 1.08
Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes (2001) 1.07
Pendred syndrome maps to chromosome 7q21-34 and is caused by an intrinsic defect in thyroid iodine organification. Nat Genet (1996) 1.07
Generation of a transcription map at the HSD17B locus centromeric to BRCA1 at 17q21. Genomics (1995) 1.07
Tumor suppressor p53 regulates heparanase gene expression. Oncogene (2006) 1.07
Leukaemic glaucoma. Br J Ophthalmol (1966) 1.06
Laser-assisted derivation of human embryonic stem cell lines from IVF embryos after preimplantation genetic diagnosis. Hum Reprod (2007) 1.06
Diet, living conditions and nasopharyngeal carcinoma in Tunisia--a case-control study. Int J Cancer (1990) 1.06
Genetics of cerebrotendinous xanthomatosis (CTX): an autosomal recessive trait with high gene frequency in Sephardim of Moroccan origin. Am J Med Genet (1981) 1.06